FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Björn Dahlöf

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Peter M Okin; Kristian Wachtell; Casper N Bang; Björn Dahlöf; Darcy A Hille; Sverre E Kjeldsen; Richard B Devereux
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Marina De Marco; Kurt Boman; Giuseppina Casalnuovo; Björn Dahlöf; Richard B Devereux; Eva Gerdts; Jorge R Kizer; Teresa Migliore; Michael H Olsen; Kristian Wachtell; Giovanni de Simone
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study.
Pawel Namsolleck; Ludovit Paulis; Katja Schwengel; Kerstin Seidel; Francesco Boato; Björn Dahlöf; Nathalie Geurts; Anders Hallberg; Sven Hendrix; Kristin Lucht; Katherine S Matho; Christa Thöne-Reineke; Thomas Unger; Ulrike Muscha Steckelings
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Björn Dahlöf (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter M Okin; Kristian Wachtell; Casper N Bang; Björn Dahlöf; Darcy A Hille; Sverre E Kjeldsen; Richard B Devereux
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Circulation. Arrhythmia and electrophysiology 2013;6(2):243-51.
2013: Marina De Marco; Kurt Boman; Giuseppina Casalnuovo; Björn Dahlöf; Richard B Devereux; Eva Gerdts; Jorge R Kizer; Teresa Migliore; Michael H Olsen; Kristian Wachtell; Giovanni de Simone
Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study.
American journal of hypertension 2013;26(4):567-73.
2013: Pawel Namsolleck; Ludovit Paulis; Katja Schwengel; Kerstin Seidel; Francesco Boato; Björn Dahlöf; Nathalie Geurts; Anders Hallberg; Sven Hendrix; Kristin Lucht; Katherine S Matho; Christa Thöne-Reineke; Thomas Unger; Ulrike Muscha Steckelings
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression.
Neurobiology of disease 2013;51():177-91.
2013: Eva Gerdts; B P Lund; Markku S Nieminen; Peter M Okin; Kristian Wachtell; K Boman; Björn Dahlöf; G de Simone; R B Devereux
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2013;23(2):122-9.
2012: Anders M Greve; Mai T Lønnebakken; Markku S Nieminen; Peter M Okin; Michael H Olsen; Per Omvik; Vittorio Palmieri; Jonathan Bella; Kurt Boman; Björn Dahlöf; Richard B Devereux; Eva Gerdts; Kristian Wachtell
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
American journal of hypertension 2012;25(9):1017-23.
2012: Anne Christine H Ruwald; Thomas Sehestedt; Kristian Wachtell; Bo Westergaard; Björn Dahlöf; Richard B Devereux; Hans Ibsen; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Michael H Olsen
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Journal of hypertension 2012;30(6):1252-9.
2012: Peter M Okin; Björn Dahlöf; Sverre E Kjeldsen; Lars H Lindholm; Richard B Devereux
The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Blood pressure 2012;21(3):146-52.
2012: Peter M Okin; Björn Dahlöf; Stevo Julius; Sverre E Kjeldsen; Richard B Devereux
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study.
Heart rhythm : the official journal of the Heart Rhythm Society 2012;9(4):531-7.
2012: Sverre E Kjeldsen; Jan Ostergren; Bertram Pitt; Jaakko Tuomilehto; Eric J Velazquez; Michael Weber; Dion Zappe; George L Bakris; Björn Dahlöf; Allen Hester; Tsushung A Hua; Hans Ibsen; Kenneth A Jamerson; Roxzana Y Kelly
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
Blood pressure 2012;21(2):82-7.
2012: Peter M Okin; Björn Dahlöf; Darcy A Hille; Stevo Julius; Sverre E Kjeldsen; Richard B Devereux
Effect of changing heart rate during treatment of hypertension on incidence of heart failure.
The American journal of cardiology 2012;109(5):699-704.
2012: Ludovit Paulis; Katja Schwengel; Svetlana Slavic; Johannes Baulmann; Sophie T R Becker; Björn Dahlöf; Elena Kaschina; Kristin Lucht; Christa Thöne-Reineke; Thomas Unger; Ulrike Muscha Steckelings
Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Hypertension 2012;59(2):485-92.
2011: Michael H Olsen; Kristian Wachtell; Hans Ibsen; Lars Lindholm; Sverre E Kjeldsen; Per Omvik; Markku S Nieminen; Björn Dahlöf; Peter M Okin; Richard B Devereux
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy.
Journal of hypertension 2011;29(5):997-1004.
2011: Peter M Okin; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Sverre E Kjeldsen; Markku S Nieminen; Jonathan M Edelman; Björn Dahlöf; Richard B Devereux
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
European journal of heart failure 2011;13(4):384-91.
2011: U Muscha Steckelings; Mats Larhed; Anders Hallberg; Robert E Widdop; Emma S Jones; Charlotta Wallinder; Pawel Namsolleck; Björn Dahlöf; Thomas Unger
Non-peptide AT2-receptor agonists.
Current opinion in pharmacology 2011;11(2):187-92.
2011: Peter M Okin; Sverre E Kjeldsen; Björn Dahlöf; Richard B Devereux
Racial differences in incident heart failure during antihypertensive therapy.
Circulation. Cardiovascular quality and outcomes 2011;4(2):157-64.
2011: Neil Chapman; Björn Dahlöf; Gene Feder; Mark Caulfield; Choon-Lan Chang; Peter S Sever; Neil R Poulter
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Ethnicity & disease 2011;21(2):150-7.
2010: Kristian Wachtell; Vittorio Palmieri; Eva Gerdts; Jonathan Bella; Gerard P Aurigemma; Vasilios Papademetriou; Björn Dahlöf; Tapio Aalto; Hans Ibsen; Jens E Rokkedal; Richard B Devereux
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
The American journal of cardiology 2010;106(7):999-1005.
2010: Peter M Okin; Sverre E Kjeldsen; Stevo Julius; Darcy A Hille; Björn Dahlöf; Jonathan M Edelman; Richard B Devereux
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
European heart journal 2010;31(18):2271-9.
2010: Peter M Okin; Eva Gerdts; Kristian Wachtell; Lasse Oikarinen; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Journal of hypertension 2010;28(7):1534-40.
2010: Peter M Okin; Darcy A Hille; Sverre E Kjeldsen; Lars H Lindholm; Jonathan M Edelman; Björn Dahlöf; Richard B Devereux
Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
American journal of hypertension 2010;23(7):786-93.
2010: Silvana Cicala; Giovanni de Simone; Eva Gerdts; Björn Dahlöf; Lars H Lindholm; Sverre E Kjeldsen; Richard B Devereux
Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2010;28(6):1134-40.
2010: Kristian Wachtell; Eva Gerdts; Gerard P Aurigemma; Kurt Boman; Björn Dahlöf; Markku S Nieminen; Michael H Olsen; Peter M Okin; Vittorio Palmieri; Jens E Rokkedal; Richard B Devereux
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Blood pressure 2010;19(3):169-75.
2010: Franziska Rompe; Metin Artuc; Anders Hallberg; Mathias Alterman; Katja Ströder; Christa Thöne-Reineke; Anne Reichenbach; Jens Schacherl; Björn Dahlöf; Michael Bader; Natalia Alenina; Markus Schwaninger; Torsten Zuberbier; Heiko Funke-Kaiser; Cosima Schmidt; Wolf-Hagen Schunck; Thomas Unger; U Muscha Steckelings
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.
Hypertension 2010;55(4):924-31.
2010: Thomas Unger; Björn Dahlöf
Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2010;11(1):75-7.
2010: Børge G Nordestgaard; Kimmo Kontula; Marianne Benn; Björn Dahlöf; Ulf de Faire; Jonathan M Edelman; Erik Eliasson; Frej Fyhrquist; Darcy A Hille; Hans Ibsen; Paulette A Lyle; Kåre Berg; Mia Sandberg; Amar A Sethi; Peggy H Wong; Ingrid Os
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Pharmacogenetics and genomics 2010;20(2):77-85.
2010: Björn Dahlöf
Cardiovascular disease risk factors: epidemiology and risk assessment.
The American journal of cardiology 2010;105(1 Suppl):3A-9A.
2009: Giovanni de Simone; Peter M Okin; Eva Gerdts; M H Olsen; Kristian Wachtell; Darcy A Hille; Björn Dahlöf; Sverre E Kjeldsen; Richard B Devereux
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2009;19(9):634-40.
2009: Marcello Chinali; Gerard P Aurigemma; Giovanni de Simone; Rakesh K Mishra; Eva Gerdts; Kristian Wachtell; Kurt Boman; Björn Dahlöf; Richard B Devereux
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy).
The American journal of cardiology 2009;104(8):1098-104.
2009: Neil R Poulter; Joanna E Dobson; Peter S Sever; Björn Dahlöf; Hans Wedel; Norm R C Campbell
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Journal of the American College of Cardiology 2009;54(13):1154-61.
2009: Peter M Okin; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Sverre E Kjeldsen; Markku S Nieminen; Jonathan Edelman; Björn Dahlöf; Richard B Devereux
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Circulation 2009;119(14):1883-91.
2009: Kurt Boman; Eva Gerdts; Kristian Wachtell; Björn Dahlöf; Markku S Nieminen; Mona Olofsson; Vasilios Papademetriou; Richard B Devereux
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009;16(2):242-8.
2009: Michael H Olsen; Kristian Wachtell; Gareth Beevers; Björn Dahlöf; Giovanni de Simone; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Paulette A Lyle; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2009;27(3):567-74.
2009: Björn Dahlöf
Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
Journal of human hypertension 2009;23(2):77-85.
2009: Sverre E Kjeldsen; Richard B Devereux; Darcy A Hille; Paulette A Lyle; Björn Dahlöf; Stevo Julius; Jonathan M Edelman; Steven M Snapinn; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Blood pressure 2009;18(6):348-61.
2009: Martin Magnusson; Stefan Jovinge; Erik Rydberg; Björn Dahlöf; Christian Hall; Olav W Nielsen; Anders Grubb; Ronnie Willenheimer
Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.
Blood pressure 2009;18(4):196-203.
2008: Elena Kaschina; Aleksandra Grzesiak; Jun Li; Anna Foryst-Ludwig; Melanie Timm; Franziska Rompe; Manuela Sommerfeld; U Rudolf Kemnitz; Caterina Curato; Pawel Namsolleck; Carsten Tschöpe; Anders Hallberg; Mathias Alterman; Thomas Hucko; Ingo Paetsch; Thomas Dietrich; Bernhard Schnackenburg; Kristof Graf; Björn Dahlöf; Ulrich Kintscher; Thomas Unger; Ulrike Muscha Steckelings
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
Circulation 2008;118(24):2523-32.
2008: Kenneth A Jamerson; Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Victor Shi; Allen Hester; Jitendra Gupte; Marjorie Gatlin; Eric Velazquez
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
The New England journal of medicine 2008;359(23):2417-28.
2008: Peter M Okin; Kristian Wachtell; Sverre E Kjeldsen; Stevo Julius; Lars H Lindholm; Björn Dahlöf; Darcy A Hille; Markku S Nieminen; Jonathan M Edelman; Richard B Devereux
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Circulation. Arrhythmia and electrophysiology 2008;1(5):337-43.
2008: Jan Ostergren; Neil R Poulter; Peter S Sever; Björn Dahlöf; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Journal of hypertension 2008;26(11):2103-11.
2008: Eva Gerdts; Dana Cramariuc; Giovanni de Simone; Kristian Wachtell; Björn Dahlöf; Richard B Devereux
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 2008;9(6):809-15.
2008: Björn Dahlöf
Preventing stroke in hypertensive patients at risk.
Journal of the American Society of Hypertension : JASH 2008;2(4 Suppl):S38-45.
2008: Eberhard Ritz; Björn Dahlöf
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Nature clinical practice. Cardiovascular medicine 2008;5 Suppl 1():S1-2.
2008: Neil Chapman; Choon-Lan Chang; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Circulation 2008;118(1):42-8.
2008: Marcello Chinali; Giovanni de Simone; Kristian Wachtell; Eva Gerdts; Julius M Gardin; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Björn Dahlöf; Richard B Devereux
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2008;26(7):1472-6.
2008: Peter M Okin; Eva Gerdts; Sverre E Kjeldsen; Stevo Julius; Jonathan Edelman; Björn Dahlöf; Richard B Devereux
Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
Hypertension 2008;52(1):100-6.
2008: Zhibin Li; Björn Dahlöf; Peter M Okin; Sverre E Kjeldsen; Kristian Wachtell; Hans Ibsen; Markku S Nieminen; Sverker Jern; Richard B Devereux
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Journal of hypertension 2008;26(6):1244-9.
2008: Vittorio Palmieri; Jonathan Bella; Eva Gerdts; Kristian Wachtell; Vasilios Papademetriou; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
American journal of hypertension 2008;21(6):701-7.
2008: Silvana Cicala; Giovanni de Simone; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2008;26(4):806-12.
2008: Ingrid Os; Veronica Franco; Sverre E Kjeldsen; Karin Manhem; Richard B Devereux; Eva Gerdts; Darcy A Hille; Paulette A Lyle; Peter M Okin; Björn Dahlöf; Suzanne Oparil
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Hypertension 2008;51(4):1103-8.
2008: Peter M Okin; Kristian Wachtell; Richard B Devereux; Markku S Nieminen; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Sverre E Kjeldsen; Stevo Julius; Björn Dahlöf
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
American journal of hypertension 2008;21(3):273-9.
2008: Sverre E Kjeldsen; Kenneth A Jamerson; George L Bakris; Bertram Pitt; Björn Dahlöf; Eric Velazquez; Jitendra Gupte; Linda Staikos; Tsushung Hua; Victor Shi; Allen Hester; Jaakko Tuomilehto; Jan Ostergren; Hans Ibsen; Michael Weber
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Blood pressure 2008;17(1):7-17.
2007: Peter M Okin; Richard B Devereux; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Lars H Lindholm; Björn Dahlöf
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
Hypertension 2007;50(5):984-90.
2007: Eigil Fossum; Gilbert W Gleim; Sverre E Kjeldsen; Jorge R Kizer; Stevo Julius; Richard B Devereux; W E Brady; Darcy A Hille; Paulette A Lyle; Björn Dahlöf
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Journal of internal medicine 2007;262(4):439-48.
2007: Peter M Okin; Richard B Devereux; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Jonathan Edelman; Björn Dahlöf
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Annals of internal medicine 2007;147(5):311-9.
2007: Marianne L Smebye; Emil K Iversen; Aud Høieggen; Arnljot Flaa; Ingrid Os; Sverre E Kjeldsen; Michael H Olsen; Arghya Chattopadhyay; Darcy A Hille; Paulette A Lyle; Richard B Devereux; Björn Dahlöf
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
The American journal of cardiology 2007;100(5):855-9.
2007: Björn Dahlöf
Prevention of stroke in patients with hypertension.
The American journal of cardiology 2007;100(3A):17J-24J.
2007: Giovanni de Simone; Michael H Olsen; Kristian Wachtell; Darcy A Hille; Björn Dahlöf; Hans Ibsen; Sverre E Kjeldsen; Paulette A Lyle; Richard B Devereux
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
Journal of human hypertension 2007;21(8):625-32.
2007: Vittorio Palmieri; Peter M Okin; Giovanni de Simone; Jonathan Bella; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Journal of hypertension 2007;25(5):1079-85.
2007: Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Hypertension 2007;49(4):839-45.
2007: Richard B Devereux; Björn Dahlöf
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Current medical research and opinion 2007;23(2):443-57.
2007: Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Katherine E Harris; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Darcy A Hille; Björn Dahlöf
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Current medical research and opinion 2007;23(2):259-70.
2007: Kenneth A Jamerson; George L Bakris; Björn Dahlöf; Bertram Pitt; Eric Velazquez; Jitendra Gupte; Martin Lefkowitz; Allen Hester; Victor Shi; Sverre E Kjeldsen; William Cushman; Vasilios Papademetriou; Michael Weber
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
Blood pressure 2007;16(2):80-6.
2007: Michael A Weber; George L Bakris; Björn Dahlöf; Bertram Pitt; Eric Velazquez; Jitendra Gupte; Martin Lefkowitz; Allen Hester; Victor Shi; Matthew R Weir; Sverre E Kjeldsen; Barrie Massie; Shawna Nesbitt; Elizabeth Ofili; Kenneth A Jamerson
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Blood pressure 2007;16(1):13-9.
2007: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Paulette A Lyle; Zhongxin Zhang; Jonathan Edelman
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Blood pressure 2007;16(1):6-12.
2006: Peter S Sever; Björn Dahlöf; Neil Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminem; Eoin O'Brien; Jan Ostergren
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
European heart journal 2006;27(24):2982-8.
2006: Vittorio Palmieri; Peter M Okin; Jonathan Bella; Kristian Wachtell; Lasse Oikarinen; Eva Gerdts; Kurt Boman; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2006;24(10):2079-84.
2006: Peter M Okin; Kristian Wachtell; Richard B Devereux; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Lars H Lindholm; Markku S Nieminen; Jonathan Edelman; Darcy A Hille; Björn Dahlöf
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
JAMA : the journal of the American Medical Association 2006;296(10):1242-8.
2006: Michael H Olsen; Kristian Wachtell; Björn Dahlöf; R B Devereux; Hans Ibsen; S E Kjeldsen; Lars H Lindholm; Paulette A Lyle; Markku S Nieminen
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Journal of human hypertension 2006;20(6):460-4.
2006: Björn Dahlöf
Prospects for the prevention of stroke.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2006;24(2):S3-9.
2006: Peter M Okin; Richard B Devereux; Eva Gerdts; Steven M Snapinn; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Jonathan Edelman; Lars H Lindholm; Björn Dahlöf
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Circulation 2006;113(12):1588-96.
2006: Steven M Haffner; Luis M Ruilope; Björn Dahlöf; Eric Abadie; Stuart Kupfer; Faiez Zannad
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
Journal of cardiovascular pharmacology 2006;47(3):469-75.
2006: Hans Ibsen; Michael H Olsen; Kristian Wachtell; Knut Borch-Johnsen; Lars H Lindholm; Carl E Mogensen; Björn Dahlöf; Steven M Snapinn; Ying Wan; Paulette A Lyle
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Diabetes care 2006;29(3):595-600.
2006: Peter M Okin; Richard B Devereux; Markku S Nieminen; Sverker Jern; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Sverre E Kjeldsen; Björn Dahlöf
Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Circulation 2006;113(1):67-73.
2005: Albert A Carr; Peter R Kowey; Richard B Devereux; Barry M Brenner; Björn Dahlöf; Hans Ibsen; Lars H Lindholm; Paulette A Lyle; Steven M Snapinn; Zhongxin Zhang; Jonathan Edelman; Shahnaz Shahinfar
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
The American journal of cardiology 2005;96(11):1530-6.
2005: Sverre E Kjeldsen; Paulette A Lyle; Andrew M Tershakovec; Richard B Devereux; Suzanne Oparil; Björn Dahlöf; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Hans Wedel
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Expert opinion on emerging drugs 2005;10(4):729-45.
2005: Björn Dahlöf; Philippe Gosse; Pascal Guéret; Olivier Dubourg; Giovanni de Simone; Roland Schmieder; Yuri Karpov; Juan García-Puig; Lajos Matos; Peter W De Leeuw; Jean-Paul Degaute; Dieter Magometschnigg
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study.
Journal of hypertension 2005;23(11):2063-70.
2005: Björn Dahlöf; Alessio Degl' Innocenti; Dag Elmfeldt; Juan Garcia Puig; Torstein Gundersen; James Hosie; Wlodzimierz Januszewicz; Carl-Johan Lindström; Dieter Magometschnigg; Paul Tanser; Pavles Toutouzas; Bernhard Waeber; Ingela Wiklund
Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction.
American journal of hypertension 2005;18(10):1313-9.
2005: Neil R Poulter; Hans Wedel; Björn Dahlöf; Peter S Sever; D Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren; Stuart Pocock
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Lancet 2005;366(9489):907-13.
2005: Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Lancet 2005;366(9489):895-906.
2005: Eigil Fossum; andreas moan; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; Steven M Snapinn; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Björn Dahlöf
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;46(5):770-5.
2005: Peter S Sever; Neil R Poulter; Björn Dahlöf; Hans Wedel
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
The American journal of cardiology 2005;96(5A):39F-44F.
2005: Bengt Jönsson; George W Carides; Thomas A Burke; Erik J Dasbach; Lars H Lindholm; Björn Dahlöf
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Journal of hypertension 2005;23(7):1425-31.
2005: Björn Dahlöf
Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
Journal of human hypertension 2005;19 Suppl 1():S9-14.
2005: Peter S Sever; Neil R Poulter; Björn Dahlöf; Hans Wedel; Rory Collins; Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Diabetes care 2005;28(5):1151-7.
2005: Giovanni de Simone; Kristian Wachtell; Vittorio Palmieri; Darcy A Hille; Gareth Beevers; Björn Dahlöf; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Richard B Devereux
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Circulation 2005;111(15):1924-31.
2005: Björn Dahlöf; E Ritz
Introduction.
Acta diabetologica 2005;42 Suppl 1():S1-2.
2005: Frej Fyhrquist; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Darcy A Hille; Paulette A Lyle; Jonathan Edelman; Steven M Snapinn; Hans Wedel
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Hypertension 2005;45(4):580-5.
2005: Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Katherine E Harris; Hans Wedel
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(3):152-8.
2005: Kristian Wachtell; Mika Lehto; Eva Gerdts; Michael H Olsen; Björn Hornestam; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Richard B Devereux
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;45(5):712-9.
2005: Kristian Wachtell; Björn Hornestam; Mika Lehto; David Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;45(5):705-11.
2005: Hans Ibsen; Michael H Olsen; Kristian Wachtell; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Hypertension 2005;45(2):198-202.
2005: Kurt Boman; Mona Olofsson; Björn Dahlöf; Eva Gerdts; Markku S Nieminen; Vasilios Papademetriou; Kristian Wachtell; Richard B Devereux
Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study).
The American journal of cardiology 2005;95(2):280-3.
2005: Erland Linjer; Thomas Hedner; Bengt Jönsson; Tord Ekbom; Lars H Lindholm; Björn Dahlöf; Ulf de Faire; Bengt Scherstén
Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Blood pressure 2005;14(2):107-13.
2005: Jorge R Kizer; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Kristian Wachtell; Jonathan Edelman; Steven M Snapinn; Katherine E Harris; Richard B Devereux
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Hypertension 2005;45(1):46-52.
2004: Richard B Devereux; Kristian Wachtell; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine Harris; Peter Aurup; Björn Dahlöf
Prognostic significance of left ventricular mass change during treatment of hypertension.
JAMA : the journal of the American Medical Association 2004;292(19):2350-6.
2004: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven M Snapinn; Katherine E Harris; Peter Aurup; Jonathan Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
JAMA : the journal of the American Medical Association 2004;292(19):2343-9.
2004: Hans Ibsen; Kristian Wachtell; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.
Kidney international. Supplement 2004;(92):S56-8.
2004: Michael H Olsen; Kristian Wachtell; Jonathan Bella; Jennifer E Liu; Kurt Boman; Eva Gerdts; Vasilios Papademetriou; Markku S Nieminen; Jens Rokkedal; Björn Dahlöf; Richard B Devereux
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
The American journal of cardiology 2004;94(8):1076-80.
2004: Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan Edelman; Kristian Wachtell
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Circulation 2004;110(11):1456-62.
2004: Kristian Wachtell; Vasilios Papademetriou; Gunnar Smith; Eva Gerdts; Björn Dahlöf; Erik Engblom; Gerard P Aurigemma; Jonathan Bella; Hans Ibsen; Jens Rokkedal; Richard B Devereux
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
American heart journal 2004;148(3):538-44.
2004: Kenneth A Jamerson; George L Bakris; Chuan-Chuan Wun; Björn Dahlöf; Martin Lefkowitz; Sheryl Manfreda; Bertram Pitt; Eric Velazquez; Michael A Weber
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
American journal of hypertension 2004;17(9):793-801.
2004: Hans Ibsen; Kristian Wachtell; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Ying Wan
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Journal of hypertension 2004;22(9):1805-11.
2004: Michele M Ciulla; Roberta Paliotti; Arturo Esposito; Javier Dìez; Begoña López; Björn Dahlöf; M Gary Nicholls; Ronald D Smith; Leen Gilles; Fabio Magrini; Alberto Zanchetti
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
Circulation 2004;110(5):552-7.
2004: Peter M Okin; Richard B Devereux; Markku S Nieminen; Sverker Jern; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Sverre E Kjeldsen; Stevo Julius; Steven M Snapinn; Björn Dahlöf
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Hypertension 2004;44(1):48-54.
2004: Henrik M Reims; Sverre E Kjeldsen; W E Brady; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):381-9.
2004: Z B Li; Kristian Wachtell; Peter M Okin; Eva Gerdts; Jennifer E Liu; Markku S Nieminen; Sverker Jern; Björn Dahlöf; Richard B Devereux
Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):397-402.
2004: Peter M Okin; Richard B Devereux; Jennifer E Liu; Lasse Oikarinen; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Kristian Wachtell; Markku S Nieminen; Björn Dahlöf
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Journal of human hypertension 2004;18(6):403-9.
2004: Jonathan Bella; Vittorio Palmieri; Kristian Wachtell; Jennifer E Liu; Eva Gerdts; Markku S Nieminen; MJ Koren; Miguel Zabalgoitia; J T Wright; Björn Dahlöf; Richard B Devereux
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Journal of human hypertension 2004;18(6):411-6.
2004: Björn Dahlöf; Thomas A Burke; K Krobot; George W Carides; Jonathan Edelman; Richard B Devereux; H-C Diener
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Journal of human hypertension 2004;18(6):367-73.
2004: Vittorio Palmieri; Kristian Wachtell; Jonathan Bella; Eva Gerdts; Vasilios Papademetriou; Markku S Nieminen; Björn Dahlöf; M J Roman; Richard B Devereux
Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):423-30.
2004: Lasse Oikarinen; Markku S Nieminen; Matti Viitasalo; Lauri Toivonen; Sverker Jern; Björn Dahlöf; Richard B Devereux; Peter M Okin
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Hypertension 2004;43(5):1029-34.
2004: Stevo Julius; Michael H Alderman; Gareth Beevers; Björn Dahlöf; Richard B Devereux; Janice G Douglas; Jonathan Edelman; Katherine E Harris; Sverre E Kjeldsen; Shawna D Nesbitt; Otelio S Randall; Jackson T Wright
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
Journal of the American College of Cardiology 2004;43(6):1047-55.
2004: Aud Høieggen; Michael H Alderman; Sverre E Kjeldsen; Stevo Julius; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Cong Chen; Björn Dahlöf
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Kidney international 2004;65(3):1041-9.
2004: Henrik M Reims; Suzanne Oparil; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; William E Brady; Frej Fyhrquist; Hans Ibsen; Lars H Lindholm; Per Omvik; Hans Wedel; Gareth Beevers; Ulf de Faire; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Björn Dahlöf
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Blood pressure 2004;13(6):376-84.
2004: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Drugs 2004;64 Suppl 2():43-60.
2004: Tord Ekbom; Erland Linjer; Thomas Hedner; Jan Lanke; Ulf de Faire; PO Wester; Björn Dahlöf; Bengt Scherstén
Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Blood pressure 2004;13(3):137-41.
2003: Kristian Wachtell; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Peter M Okin; Per Omvik; Suzanne Oparil; Hans Wedel; Steven M Snapinn; Peter Aurup
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Annals of internal medicine 2003;139(11):901-6.
2003: Lars H Lindholm; Björn Dahlöf; Jonathan Edelman; Hans Ibsen; Knut Borch-Johnsen; Michael H Olsen; Steven M Snapinn; Kristian Wachtell
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Lancet 2003;362(9384):619-20.
2003: Richard B Devereux; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Peter Aurup; Gareth Beevers; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Sigrid Helle Berg; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Annals of internal medicine 2003;139(3):169-77.
2003: Lasse Oikarinen; Markku S Nieminen; Lauri Toivonen; Matti Viitasalo; Kristian Wachtell; Vasilios Papademetriou; Sverker Jern; Björn Dahlöf; Richard B Devereux; Peter M Okin
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
American heart journal 2003;145(5):919-25.
2003: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet 2003;361(9364):1149-58.
2003: Vittorio Palmieri; Jonathan Bella; Mary J Roman; Eva Gerdts; Vasilios Papademetriou; Kristian Wachtell; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study.
Journal of hypertension 2003;21(4):781-7.
2003: Gerard P Aurigemma; Richard B Devereux; Kristian Wachtell; Vittorio Palmieri; Kurt Boman; Eva Gerdts; Markku S Nieminen; Vasilios Papademetriou; Björn Dahlöf
Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.
American journal of hypertension 2003;16(3):180-6.
2003: Vittorio Palmieri; Peter M Okin; Jonathan Bella; Eva Gerdts; Kristian Wachtell; Julius Gardin; Vasilios Papademetriou; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Hypertension 2003;41(1):75-82.
2002: Kristian Wachtell; Björn Dahlöf; Jens Rokkedal; Vasilios Papademetriou; Markku S Nieminen; Gunnar Smith; Eva Gerdts; Kurt Boman; Jonathan Bella; Richard B Devereux
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
American heart journal 2002;144(6):1057-64.
2002: Alberto Zanchetti; Lennart Hansson; Björn Dahlöf; Stevo Julius; Joël Ménard; Ingrid Warnold; Hans Wedel
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk.
Journal of hypertension 2002;20(11):2301-7.
2002: Sverre E Kjeldsen; Björn Dahlöf; Richard B Devereux; Stevo Julius; Peter Aurup; Jonathan Edelman; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
JAMA : the journal of the American Medical Association 2002;288(12):1491-8.
2002: Philippe Gosse; Olivier Dubourg; Pascal Guéret; Giovanni de Simone; Roland Schmieder; Peter W De Leeuw; Jean-Paul Degaute; Juan García-Puig; Yuri Karpov; Dieter Magometschnigg; Lajos Matos; P Amouyel; Roland Asmar; J-Y Le Heuzey; M Nieminen; Björn Dahlöf
Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design.
Journal of human hypertension 2002;16(9):653-9.
2002: Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael H Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2002;20(9):1879-86.
2002: Peter M Okin; Jackson T Wright; Markku S Nieminen; Sverker Jern; Anne L Taylor; Robert Phillips; Vasilios Papademetriou; Luther Clark; Elizabeth Ofili; Otelio S Randall; Lasse Oikarinen; Matti Viitasalo; Lauri Toivonen; Stevo Julius; Björn Dahlöf; Richard B Devereux
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
American journal of hypertension 2002;15(8):663-71.
2002: Kristian Wachtell; Vittorio Palmieri; Michael H Olsen; Eva Gerdts; Vasilios Papademetriou; Markku S Nieminen; Gunnar Smith; Björn Dahlöf; Gerard P Aurigemma; Richard B Devereux
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Circulation 2002;106(2):227-32.
2002: Richard B Devereux; Vittorio Palmieri; Jennifer E Liu; Kristian Wachtell; Jonathan Bella; Kurt Boman; Eva Gerdts; Markku S Nieminen; Vasilios Papademetriou; Björn Dahlöf
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Journal of hypertension 2002;20(7):1445-50.
2002: Sverre E Kjeldsen; Thomas Hedner; Jan Otto Syvertsen; Per Lund-Johansen; Lennart Hansson; Jan Lanke; Lars H Lindholm; Ulf de Faire; Björn Dahlöf; Bengt E Karlberg
Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study.
Journal of hypertension 2002;20(6):1231-7.
2002: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):1004-10.
2002: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):995-1003.
2002: Kristian Wachtell; Jonathan Bella; Jens Rokkedal; Vittorio Palmieri; Vasilios Papademetriou; Björn Dahlöf; Tapio Aalto; Eva Gerdts; Richard B Devereux
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Circulation 2002;105(9):1071-6.
2002: Kristian Wachtell; Michael H Olsen; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Markku S Nieminen; Peter M Okin; Vasilios Papademetriou; Carl E Mogensen; Knut Borch-Johnsen; Hans Ibsen
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2002;20(3):405-12.
2002: John B Kostis; Stuart M Cobbe; Colin Johnston; Ian Ford; Michael B. Murphy; Michael A Weber; Henry R Black; Pierre-François Plouin; Daniel Levy; Guiseppe Mancia; Pierre Larochelle; Rainer E Kolloch; Michael H Alderman; Luis M Ruilope; Björn Dahlöf; John M Flack; Robert Wolf
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.
American journal of hypertension 2002;15(2 Pt 1):193-8.
2002: Kristian Wachtell; Vittorio Palmieri; Michael H Olsen; Jonathan Bella; Tapio Aalto; Björn Dahlöf; Eva Gerdts; Jackson T Wright; Vasilios Papademetriou; Carl E Mogensen; Knut Borch-Johnsen; Hans Ibsen; Richard B Devereux
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.
American heart journal 2002;143(2):319-26.
2002: Jonathan Bella; Kristian Wachtell; Kurt Boman; Vittorio Palmieri; Vasilios Papademetriou; Eva Gerdts; Tapio Aalto; Michael H Olsen; Mona Olofsson; Björn Dahlöf; Mary J Roman; Richard B Devereux
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study).
The American journal of cardiology 2002;89(3):337-41.
2001: Lasse Oikarinen; Markku S Nieminen; Matti Viitasalo; Lauri Toivonen; Kristian Wachtell; Vasilios Papademetriou; Sverker Jern; Björn Dahlöf; Richard B Devereux; Peter M Okin
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction.
Journal of hypertension 2001;19(10):1883-91.
2001: Miguel Zabalgoitia; J Berning; MJ Koren; A Støylen; Markku S Nieminen; Björn Dahlöf; Richard B Devereux
Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study).
The American journal of cardiology 2001;88(6):646-50.
2001: Lars H Lindholm; H Anderson; Tord Ekbom; Lennart Hansson; Jan Lanke; Björn Dahlöf; Ulf de Faire; K Forsén; Thomas Hedner; Erland Linjer; Bengt Scherstén; PO Wester; Torgil R Möller
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial.
Lancet 2001;358(9281):539-44.
2001: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Journal of human hypertension 2001;15 Suppl 1():S11-2.
2001: Peter M Okin; Richard B Devereux; Sverker Jern; Stevo Julius; S E Kjeldsen; Björn Dahlöf
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
American journal of hypertension 2001;14(8 Pt 1):775-82.
2001: Alberto Zanchetti; Lennart Hansson; Björn Dahlöf; Dag Elmfeldt; Sverre E Kjeldsen; Rainer E Kolloch; P Larochelle; Gordon T McInnes; JM Mallion; Luis M Ruilope; Hans Wedel
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.
Journal of hypertension 2001;19(6):1149-59.
2001: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
Journal of hypertension 2001;19(6):1139-47.
2001: Vittorio Palmieri; Kristian Wachtell; Eva Gerdts; Jonathan Bella; Vasilios Papademetriou; Christian Tuxen; Markku S Nieminen; Björn Dahlöf; Giovanni de Simone; Richard B Devereux
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
American heart journal 2001;141(5):784-91.
2001: Björn Dahlöf
Left ventricular hypertrophy and angiotensin II antagonists.
American journal of hypertension 2001;14(2):174-82.
2001: Richard Devereux; Jonathan Bella; Kurt Boman; Eva Gerdts; Markku S Nieminen; Jens Rokkedal; Vasilios Papademetriou; Kristian Wachtell; J Wright; Mary Paranicas; Peter M Okin; Mary J Roman; G Smith; Björn Dahlöf
Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study.
Blood pressure 2001;10(2):74-82.
2001: Jonathan Bella; Kristian Wachtell; Vittorio Palmieri; P R Liebson; Eva Gerdts; A Ylitalo; MJ Koren; O L Pedersen; Jens Rokkedal; Björn Dahlöf; Mary J Roman; Richard B Devereux
Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.
Journal of hypertension 2001;19(1):127-34.
2001: Kristian Wachtell; Jens Rokkedal; Jonathan Bella; Tapio Aalto; Björn Dahlöf; G Smith; Mary J Roman; Hans Ibsen; Gerard P Aurigemma; Richard B Devereux
Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint.
The American journal of cardiology 2001;87(1):54-60.
2000: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Björn Dahlöf
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Hypertension 2000;36(5):766-73.
2000: Lars H Lindholm; Lennart Hansson; Tord Ekbom; Björn Dahlöf; Jan Lanke; Erland Linjer; Bengt Scherstén; PO Wester; Thomas Hedner; Ulf de Faire
Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.
Journal of hypertension 2000;18(11):1671-5.
2000: Sverre E Kjeldsen; Björn Dahlöf; R B Devereux; Stevo Julius; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
American journal of hypertension 2000;13(8):899-906.
2000: Ronnie Willenheimer; Björn Dahlöf; A Gordon
Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance?
Heart (British Cardiac Society) 2000;84(2):129-33.
2000: Lennart Hansson; Thomas Hedner; Per Lund-Johansen; Sverre E Kjeldsen; Lars H Lindholm; Jan Otto Syvertsen; Jan Lanke; Ulf de Faire; Björn Dahlöf; Bengt E Karlberg
Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.
Lancet 2000;356(9227):359-65.
2000: Kristian Wachtell; G Smith; Eva Gerdts; Björn Dahlöf; Markku S Nieminen; Vasilios Papademetriou; Jonathan Bella; Hans Ibsen; Jens Rokkedal; Richard B Devereux
Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
The American journal of cardiology 2000;85(4):466-72.
2000: Peter M Okin; Sverker Jern; Richard B Devereux; Sverre E Kjeldsen; Björn Dahlöf
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Hypertension 2000;35(1 Pt 1):13-8.
2000: Kristian Wachtell; Jonathan Bella; P R Liebson; Eva Gerdts; Björn Dahlöf; Tapio Aalto; Mary J Roman; Vasilios Papademetriou; Hans Ibsen; Jens Rokkedal; Richard B Devereux
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study.
Hypertension 2000;35(1 Pt 1):6-12.
1999: Lennart Hansson; Lars H Lindholm; Tord Ekbom; Björn Dahlöf; Jan Lanke; Bengt Scherstén; PO Wester; Thomas Hedner; Ulf de Faire
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
Lancet 1999;354(9192):1751-6.
1999: V Palmieri; Björn Dahlöf; V DeQuattro; N Sharpe; Jonathan Bella; Giovanni de Simone; Mary Paranicas; D Fishman; R B Devereux
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement.
Journal of the American College of Cardiology 1999;34(5):1625-32.
1999: B Waeber; J M Detry; Björn Dahlöf; Juan Garcia Puig; T Gundersen; James Hosie; W Januszewicz; C J Lindström; Dieter Magometschnigg; M Safar; P Tanser; P Toutouzas
Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?
American journal of hypertension 1999;12(9 Pt 1):915-20.
1999: Lennart Hansson; Lars H Lindholm; Leo Niskanen; Jan Lanke; Thomas Hedner; Anders Niklason; K Luomanmäki; Björn Dahlöf; Ulf de Faire; C Mörlin; Bengt E Karlberg; PO Wester; J E Björck
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Lancet 1999;353(9153):611-6.
1998: Björn Dahlöf; Richard B Devereux; Stevo Julius; Sverre E Kjeldsen; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Thomas Hedner; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Hypertension 1998;32(6):989-97.
1998: Lennart Hansson; Alberto Zanchetti; S G Carruthers; Björn Dahlöf; Dag Elmfeldt; Stevo Julius; J Ménard; K H Rahn; Hans Wedel; S Westerling
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Lancet 1998;351(9118):1755-62.
1998: Hans Herlitz; Björn Dahlöf; Olof Jonsson; Peter Friberg
Relationship between salt and blood pressure in hypertensive patients on chronic ACE-inhibition.
Blood pressure 1998;7(1):47-52.
1997: Lennart Hansson; Thomas Hedner; L Lindholm; Anders Niklason; K Luomanmäki; Leo Niskanen; Jan Lanke; Björn Dahlöf; Ulf de Faire; C Mörlin; Bengt E Karlberg; PO Wester; J E Björck
The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status.
Blood pressure 1997;6(6):365-7.
1997: Björn Dahlöf; Lars H Lindholm; S Carney; P J Pentikäinen; Jan Ostergren
Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group.
Journal of hypertension 1997;15(11):1327-35.
1997: Björn Dahlöf; R Devereux; Ulf de Faire; Frej Fyhrquist; Thomas Hedner; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
American journal of hypertension 1997;10(7 Pt 1):705-13.
1996: L H Lindholm; L Hansson; Björn Dahlöf; T Ekbom; T Hedner; Ulf de Faire; B Scherstén; PO Wester
The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report.
Blood pressure 1996;5(5):300-4.
1995: Björn Dahlöf
Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Journal of human hypertension 1995;9 Suppl 5():S37-44.
1995: Björn Dahlöf; S E Keller; L Makris; A I Goldberg; C S Sweet; N Y Lim
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
American journal of hypertension 1995;8(6):578-83.
1994: T Ekbom; L H Lindholm; A Odén; Björn Dahlöf; L Hansson; P O Wester; B Scherstén
A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people.
Journal of internal medicine 1994;235(6):581-8.
1994: Björn Dahlöf
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
Blood pressure. Supplement 1994;2():35-40.
1993: Björn Dahlöf; L Hansson; L H Lindholm; B Scherstén; T Ekbom; PO Wester
Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1993;15(6):925-39.
1993: M Johannesson; Björn Dahlöf; L H Lindholm; T Ekbom; L Hansson; A Odén; B Scherstén; P O Wester; Bengt Jönsson
The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension).
Journal of internal medicine 1993;234(3):317-23.
1993: Björn Dahlöf; L Hansson
The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide.
Journal of internal medicine 1993;234(3):271-9.
1993: Björn Dahlöf; L Hansson; L H Lindholm; B Scherstén; PO Wester; T Ekbom; Thomas Hedner; Ulf de Faire
STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension.
Blood pressure 1993;2(2):136-41.
1993: Björn Dahlöf
The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1993;11(3):S29-35.
1993: Björn Dahlöf; L Jönsson; O Borgholst; G Ekblad; C Engstrand; I Grundestam; A Lindh
Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone.
Blood pressure. Supplement 1993;1():37-45.
1993: Björn Dahlöf; J Hosie
Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group.
Blood pressure. Supplement 1993;1():22-9.
1992: T Ekbom; Björn Dahlöf; L Hansson; L H Lindholm; B Scherstén; PO Wester
Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study.
Journal of hypertension 1992;10(12):1525-30.
1992: Björn Dahlöf; L Hansson
Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide.
Journal of hypertension 1992;10(12):1513-24.
1992: Björn Dahlöf; Hans Herlitz; Mattias Aurell; L Hansson
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system.
American journal of hypertension 1992;5(12 Pt 1):900-11.
1992: T Ekbom; Björn Dahlöf; L Hansson; L H Lindholm; A Odén; B Scherstén; PO Wester
The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure--insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).
Blood pressure 1992;1(3):168-72.
1992: L Hansson; Thomas Hedner; Björn Dahlöf
Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point.
Blood pressure 1992;1(2):113-9.
1992: Björn Dahlöf; S Stenkula; L Hansson
Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment.
Blood pressure 1992;1(1):35-44.
1992: Björn Dahlöf; K Pennert; L Hansson
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.
American journal of hypertension 1992;5(2):95-110.
1992: Björn Dahlöf; K Pennert; L Hansson
Regression of left ventricular hypertrophy--a meta-analysis.
Clinical and experimental hypertension. Part A, Theory and practice 1992;14(1-2):173-80.
1992: Björn Dahlöf
Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy.
Blood pressure. Supplement 1992;6():1-75.
1991: Ulf de Faire; Björn Dahlöf; I Enström; L Hansson; T Hedner; Jan Lanke; L Lindholm; O Samuelsson; A Schwan; T Thulin
[Ambulatory blood pressure measurement--guidelines for registration and data processing].
Läkartidningen 1991;88(50):4352-5.
1991: Björn Dahlöf; T Ekbom; L Hansson; L Lindholm; B Scherstén; PO Wester
[Antihypertensive treatment reduces the risk of stroke even in elderly hypertensive patients].
Läkartidningen 1991;88(49):4229-30.
1991: Björn Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; PO Wester
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Lancet 1991;338(8778):1281-5.
1991: L Hansson; Björn Dahlöf; T Ekbom; L Lindholm; B Scherstén; PO Wester
Key learnings from the STOP-Hypertension study: an update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1991;4 Suppl 6():1253-5.
1991: Sverker Jern; L Hansson; B Scherstén; S Kullman; S Sörensen; Björn Dahlöf; R Eggertsen; R Sivertsson
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
Journal of cardiovascular pharmacology 1991;18 Suppl 3():S7-8.
1990: Björn Dahlöf; D Gustafsson; Thomas Hedner; Sverker Jern; L Hansson
Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction.
Journal of hypertension 1990;8(9):811-7.
1990: Björn Dahlöf
Regression of cardiovascular structural changes--a preventive strategy.
Clinical and experimental hypertension. Part A, Theory and practice 1990;12(5):877-96.
1990: Björn Dahlöf
Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review.
Cor et vasa 1990;32(2 Suppl 1):23-34.
1990: L Hansson; Björn Dahlöf
Calcium antagonists in the treatment of hypertension: state of the art.
Journal of cardiovascular pharmacology 1990;15 Suppl 4():S71-5.
1989: Björn Dahlöf
Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension.
The American journal of medicine 1989;86(4A):19-26.
1989: R Eggertsen; A Svensson; Björn Dahlöf; L Hansson
Additive effect of isradipine in combination with captopril in hypertensive patients.
The American journal of medicine 1989;86(4A):124-6.
1988: T Ekbom; L Lindholm; A Odén; Björn Dahlöf; L Hansson; B Scherstén; PO Wester
Blood pressure does not predict mortality in the elderly.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(4):S626-8.
1988: L Hansson; Björn Dahlöf; T Gudbrandsson; T Hellsing; S Kullman; J Kuylenstierna; J Leppert; B Möller; K Skogström; A Svensson
Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy.
Journal of cardiovascular pharmacology 1988;12(1):94-101.
1988: Björn Dahlöf; L Hansson; J H Acosta; K Bolzano; G Fairhurst; C Ferreira; E Kaarsalo; M C Silva; A Simone
Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients.
American journal of hypertension 1988;1(1):38-41.
1988: Björn Dahlöf; R Eggertsen; L Hansson
Calcium antagonists combined with beta-blockers or ACE inhibitors in the treatment of hypertension.
Journal of cardiovascular pharmacology 1988;12 Suppl 6():S104-8.
1987: Björn Dahlöf; L Andrén; R Eggertsen; Sverker Jern; A Svensson; L Hansson
The long-term effect of isradipine in pindolol-treated patients.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1987;5(5):S567-70.
1987: Björn Dahlöf; L Hansson; L Lindholm; B Schersten; PO Wester
STOP-Hypertension--preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1987;5(5):S607-10.
1987: Björn Dahlöf
The role of antihypertensive pharmacologic treatment in countering adverse pathophysiological profiles: influence on small arteries.
American heart journal 1987;114(4 Pt 2):984-91.
1987: Björn Dahlöf; L Andrén; R Eggertsen; Sverker Jern; A Svensson; A Sievert; Mattias Aurell; L Hansson
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension.
Journal of cardiovascular pharmacology 1987;10 Suppl 10():S102-4.
1985: Björn Dahlöf; L Andrén; R Eggertsen; Sverker Jern; A Svensson; L Hansson
Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1985;3(3):S483-6.
1983: L Andrén; Björn Dahlöf; R Eggertsen; T Gudbrandsson; L Hansson; S Jern; R Sivertsson; A Svensson
[A review of recent pharmacological therapeutic principles in hypertension].
Läkartidningen 1983;80(10):945-58.
1983: L Andrén; Björn Dahlöf; R Eggertsen; T Gudbrandsson; L Hansson; S Jern; R Sivertsson; A Svensson
[Review of new pharmacological treatment principles in hypertension].
Nordisk medicin 1983;98(5):136-41.